… evaluate the pattern of clinical use of three EGFR TKIs (afatinib, gefitinib, and erlotinib). We
found that gefitinib was more commonly used than erlotinib or afatinib in Korea, especially for …

… [23], [24], [25], [26], [27], [28], [29], [30] In this study, we explored the outcomes of some
relatively frequent single uncommon EGFR mutations, and differences in efficacy and prognosis …

… The adverse reactions most commonly observed during EGFRI (erlotinib and gefitinib) … be
EGFR mutated, 22.5 per cent were non-mutated and others were not tested for EGFR mutation …

… /IV EGFR-mutant NSCLC were treated with pembrolizumab 2 mg/kg intravenously every 3
weeks plus oral erlotinib 150 mg daily in cohort E or oral gefitinib … The most frequent treatment-…

… The most common mutations were the deletion in exon 19 and … provides evidence that
gefitinib, erlotinib, and afatinib have similar effectiveness in advance stage EGFR mutation lung …

… Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) commonly are …
including impacts on secondary EGFR T790M mutation, the most frequent EGFR-TKI resistance …

… Both gefitinib and erlotinib have been … with gefitinib in 319 treatment-naive patients (160
randomized to afatinib and 159 to gefitinib) with NSCLC harboring common EGFR mutations (…

… with gefitinib or erlotinib after adjusting for both EGFR mutation … among the three most
commonly available TKIs. Therefore, … most commonly available first- or second-generation EGFR …

… largely concentrated on common EGFR mutations, reflecting … analysis of compound EGFR
mutations (two uncommon mutations) … to different EGFR TKIs (erlotinib, gefitinib, afatinib, and …

… We performed EGFR mutation tests by using the peptide nucleic acid … EGFR T790 M mutation
is the most common resistance mechanism to first-generation EGFR-TKIs (gefitinib, erlotinib…